FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products

Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…

AI Summary: The FDA is consolidating multiple safety reporting systems into a single public Adverse Event Monitoring System to centralize reports for drugs, biologics, vaccines, cosmetics and animal products. The move aims to improve transparency, reduce fragmented reporting, and streamline monitoring — a tidy solution if it works as promised.